The economic benefits of Covid-19 vaccines in their first year may be roughly double what earlier estimates suggested, according to a revised analysis covering 173 countries. The study, published in PLOS Medicine, puts the potential first-year benefits at up to $64.3 trillion, compared with an earlier range of $4.8 trillion to $37.9 trillion. The new work effectively brings the headline figure close to twice the previous upper estimate.
The updated figures set those benefits against a development cost of about $79.4 billion invested globally. Researchers estimate the vaccines returned between roughly $59.70 and $809 for every $1 spent in the first year. The revised range runs from $6.43 trillion under a cost-effectiveness approach to $64.3 trillion under a cost-benefit approach, so the answer depends heavily on how the analysis is framed.
The analysis counts several inputs: hospitalisations averted, productivity losses avoided and lives saved. The modelling credits the vaccines with preventing between 14 million and 20 million deaths in the first year. Lead institutions include the London School of Hygiene and Tropical Medicine and New York University, and the work also drew commentary from a researcher at the University of California, Riverside. Each of these inputs feeds into the overall totals, which is why small changes in assumptions can move the result by large amounts.
Much of the increase in the cost-benefit figure comes from a change in method. The earlier estimates valued avoided deaths using Value of Statistical Life Years, while the revised work uses the Value of Statistical Life. That shift in how avoided deaths are valued accounts mainly for the higher cost-benefit result, and it is the reason the new estimate is not a simple update of the old one.
The earlier figures were preprint estimates, released before peer review, and the new study has now been published in a peer-reviewed journal. That distinction matters for how the numbers should be read: the revised version has passed external scrutiny, while the earlier version had not.
The returns were also uneven across the world. Richer countries saw the highest returns, while poorer countries received vaccines later. The authors say a fairer global distribution of vaccines is needed, arguing that the gap in access carried real economic and human costs. In other words, the benefits that the study measures were not shared equally, and the delay in reaching lower-income nations represents a loss that the headline totals alone do not show.